Showing results (171-180 of 188) with videos related to
Sort By:
Pageof 19
Journal of Thoracic Disease|March 12, 2026
Relationship between immune-related adverse events and treatment outcome of immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective cohort studyTakafumi Hashimoto, Takashi Karashima, Kosuke Kamada, et al.European Journal of Cancer (Oxford, England : 1990)|March 26, 2023
Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL StudyRyota Saito, Shunichi Sugawara, Ryo Ko, et al.Cureus|July 24, 2025
Retreatment With EGFR-Tyrosine Kinase Inhibitor After Disease Progression Following Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant Stage III Non-small Lung Cancer: An Efficacy and Safety Analysis of the LOGIK0902/OLCSG0905 StudySho Saeki, Katsuyuki Hotta, Shinya Sakata, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2021
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT)Hirohito Tada, Tetsuya Mitsudomi, Toshihiro Misumi, et al.International Journal of Clinical Oncology|February 5, 2025
Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II studyKatsuyuki Hotta, Sho Saeki, Shinya Sakata, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2023
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung CancerHirotsugu Kenmotsu, Nobuyuki Yamamoto, Toshihiro Misumi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2020
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung CancerHirotsugu Kenmotsu, Nobuyuki Yamamoto, Takeharu Yamanaka, et al.JTO Clinical and Research Reports|December 4, 2023
A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)Kazushige Wakuda, Hiroyuki Yamaguchi, Hirotsugu Kenmotsu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2021
A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L)Hiroyuki Yamaguchi, Kazushige Wakuda, Minoru Fukuda, et al.The Oncologist|April 17, 2020
Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401Eiji Iwama, Yasushi Goto, Haruyasu Murakami, et al.Pageof 19